Bluebird bio has found a new nest with Carlyle and SK Capital. Credit: pchoui via Getty Images. Bluebird bio will be acquired by investment firms Carlyle and SK Capital Partners, marking the end to its turbulent time as a publicly […]
Struggling bluebird bio to go private for less than $30m Read More »
NICE estimates that these therapies could help nearly 700 patients per year in England. Credit: krisanapong detraphiphat via Getty Images. Two blood cancer treatments will now be available on the UK’s National Health Service (NHS) following recommendations from the National
NICE green lights two blood cancer therapies for NHS use Read More »
FibroGen’s headquarters in San Francisco, US. Credit: Sundry Photography via Getty Images. AstraZeneca has agreed to acquire FibroGen’s China subsidiary for approximately $160m, securing full control over the anaemia drug roxadustat in the country. The deal strengthens AstraZeneca’s presence in
FibroGen sells China unit to AstraZeneca for $160m Read More »
Zealand Pharma is based in Denmark. Credit: Zealand Pharma via LinkedIn. Zealand Pharma’s search for a partner for its amylin-based obesity therapy petrelintide remains ongoing, with no agreement announced in its 2024 earnings report. The company has yet to secure
Zealand Pharma steadfastly upholds amylin-based obesity drug strategy Read More »
The Phase IIb study enrolled 250 adult patients with treatment-resistant depression. Credit: Justin Paget via Getty Images. Supernus Pharmaceutical’s stock declined following the release of disappointing Phase IIb trial results for SPN-820, an investigational treatment for adults with treatment-resistant depression
Supernus’s stock sinks after depression drug fails trial Read More »
There is a demand for new, non-addictive treatments for opioid use disorder. Credit: sorbetto via Getty Images. Glucagon-like peptide receptor agonists (GLP-1RAs) like Novo Nordisk’s semaglutide (Ozempic, Wegovy) and Eli Lilly’s tirzepatide (Mounjaro, Zepbound) have dominated headlines for their blockbuster
GLP-1RAs and opioid use disorder: a new frontier in addiction treatment Read More »
AWS reported $107.6bn in revenue in 2024. Credit: Noah Berger via Getty Images. Amazon Web Services (AWS) and US-based Memorial Sloan Kettering Cancer Center (MSK) have announced a partnership to leverage artificial intelligence (AI), high-performance computing (HPC), and cloud technology
Amazon joins forces with Memorial Sloan Kettering for AI-powered drug discovery Read More »
If approved, lenacapavir would be the first twice-yearly HIV prevention choice. Credit: Ulrich Baumgarten via Getty Images. Gilead is edging closer to an approval for its twice-yearly injectable human immunodeficiency virus-1 (HIV-1) capsid inhibitor, lenacapavir, as a pre-exposure prophylaxis (PrEP)
Gilead’s lenacapavir moves closer to FDA approval for HIV PrEP use Read More »
Regeneron and Sanofi have collaborated on Dupixent since 2007. Credit: The Washington Post via Getty Images. Sanofi and Regeneron’s blockbuster biologic Dupixent (dupilumab) is poised for yet another label expansion, this time for the rare autoimmune skin disorder bullous pemphigoid
FDA to review Sanofi and Regeneron’s Dupixent sBLA for bullous pemphigoid Read More »
TGCT is a rare, non-cancerous tumour affecting the joints, tendons, or joint tissue. Credit: Kinga Krzeminska via Getty Images. Ono Pharmaceutical has secured approval from the US Food and Drug Administration (FDA) for its kinase inhibitor Romvimza (vimseltinib) to treat
Ono’s TGCT therapy wins FDA approval, challenging Daiichi Sankyo Read More »
